Skip to main content
OpenTrials
Completed

NCT Number: NCT03355755

Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury

A safety and feasibility study of robotic exoskeleton training in deconditioned patients residing in a healthcare facility.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gaylord Specialty Healthcare, Wallingford, Connecticut, United States

Loading trial locations.

About this study

Patients who are hospitalized for several weeks or months are at a higher risk of decline in physical condition and are also at a higher risk of rehospitalization within 30 days of discharge. A program incorporating robotic exoskeleton training may provide sufficient physical support and challenge for patients to maintain a higher level of physical condition than if they did not undergo exoskeleton training. The investigators aim to demonstrate that EksoGT robotic exoskeleton training can be performed safely with patients who have been hospitalized and are at risk of experiencing a further decline in their physical condition.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of "deconditioned", defined as the loss of muscle tone and endurance due to chronic disease, immobility, or loss of function.
  • Adults 18 years and older (or as specified by state law).
  • Admitted into a hospital, long-term care facility, skilled nursing facility, or similar.
  • Sufficient upper extremity strength to use a front wheeled walker by manual muscle testing (minimum triceps strength bilaterally of 3/5, shoulder abduction and flexion/extension 4/5).
  • Screened and cleared by a physician for full weight-bearing exercise training.
  • Weigh 220 pounds (100kg) or less.
  • Between approximately 5'0" and 6'4" tall.
  • Standing hip width of approximately 18" or less.
  • Have near normal range of motion in hips, knees and ankles.

Exclusion criteria

  • Currently involved in another intervention study.
  • Transferred to the intensive care unit or isolation-room stay.
  • Currently on a ventilator or extracorporeal membrane oxygenation (ECMO) machine.
  • Currently have a ventricular assist device (VAD) or an automatic implantable cardioverter-defibrillator (AICD).
  • Advanced heart failure - ejection fraction of < 20%.
  • Documented cardiovascular risk from exercise.
  • Resting heart rate <50 bpm or >120 bpm.
  • Uncontrolled or new (within 24 hours) arrythmias.
  • Resting blood pressure below 90/70 or above 160/100.
  • Oxygen saturation (O2 sat) < 90% during rest.
  • Uncontrolled or severe orthostatic hypotension that limits standing tolerance.
  • Cardiac ischemia within 24 hours.
  • Unresolved or new (within 24 hours) deep vein thrombosis.
  • Concurrent severe neurological pathology/disease or stroke within 72 hours.
  • Open skin ulcerations on any body surfaces in contact with exoskeleton.
  • Acute fracture
  • Osteoporosis
  • Active heterotrophic ossification (HO) of the lower extremity, hip dysplasia, or hip/knee axis abnormalities.
  • Current chemotherapy
  • Inability to speak or understand the English language.
  • Inability to cooperate in tests/exercises.
  • Hip flexion contracture greater than ~17°.
  • Knee flexion contracture greater than 12°.
  • Unable to achieve neutral ankle dorsiflexion with passive stretch (neutral with max 12° knee flexion).
  • Cognitive impairments - unable to follow 2 step commands or to communicate pain or to stop session.
  • Pregnancy
  • Any reason the physician may deem as harmful to the participant to enroll or continue in the study.

Treatment and study plan

EksoGT with SmartAssist software

Device

Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event During Time of Treatment

    Time frame: 2 weeks

    The primary endpoint is safety defined as the number of participants experiencing an adverse event per overall during the study period.

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event During Time of Treatment That Was Deemed "Definitely Device Related"

    Time frame: 2 weeks

    Count of number of participants who experienced any adverse event that was rated as definitely related to treatment with the Ekso device.

Sponsors and collaborators

Lead sponsor

Ekso Bionics

Industry

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Nov 28, 2017
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.